Sort   by:  
 Page size 
UnknownThe UGT1A9*22 genotype identifies a high-risk group for irinotecan toxicity among gastric cancer patients.
Not available
S-EPMC9576471 | biostudies-literature
UnknownHigh levels of baseline serum IL-10 are associated with reduced clinical benefit from first-line immune checkpoint inhibitor therapy in advanced renal cell carcinoma.
Not available
S-EPMC10158513 | biostudies-literature
UnknownDeep learning model enables the discovery of a novel immunotherapeutic agent regulating the kynurenine pathway.
Not available
S-EPMC8632076 | biostudies-literature
UnknownAssociation of High Levels of Antidrug Antibodies Against Atezolizumab With Clinical Outcomes and T-Cell Responses in Patients With Hepatocellular Carcinoma.
Not available
S-EPMC9585463 | biostudies-literature
UnknownEfficacy and safety of second-line nab-paclitaxel plus gemcitabine after progression on FOLFIRINOX for unresectable or metastatic pancreatic ductal adenocarcinoma: multicenter retrospective analysis.
Not available
S-EPMC7257856 | biostudies-literature
UnknownAtezolizumab plus bevacizumab in patients with child-Pugh B advanced hepatocellular carcinoma.
Not available
S-EPMC10495918 | biostudies-literature
UnknownHigh Serum Levels of IL-6 Predict Poor Responses in Patients Treated with Pembrolizumab plus Axitinib for Advanced Renal Cell Carcinoma.
Not available
S-EPMC9738341 | biostudies-literature
UnknownThyroid Dysfunction after Atezolizumab and Bevacizumab Is Associated with Favorable Outcomes in Hepatocellular Carcinoma.
Not available
S-EPMC10857827 | biostudies-literature
UnknownHigh serum IL-6 correlates with reduced clinical benefit of atezolizumab and bevacizumab in unresectable hepatocellular carcinoma.
Not available
S-EPMC9972403 | biostudies-literature
UnknownOutcomes of Nivolumab Plus Ipilimumab After Atezolizumab Plus Bevacizumab in Advanced HCC: An International Multicentre Study.
Not available
S-EPMC12742031 | biostudies-literature
Sort   by:  
 Page size